RESUMEN
Human rhinoviruses (HRV) are the main cause of the common cold. Viral replication utilizes the activity of the HRV3C protease (3CP) enzyme [Antimicrob. Agents Chemother. 43 (1999) 2444; Antimicrob. Agents Chemother. 44 (2000) 1236]. Therefore, 3CP is an attractive target for antiviral drug development, and a new class of orally bioavailable irreversible 3CP inhibitors has been designed [J. Med. Chem. 45 (2002) 1607]. We have used related inhibitors to develop a rapid test for rhinovirus. The optical immuno assay (OIA) thin film detection technology utilizes an optically coated silicon surface to convert specific molecular binding events into visual color changes by altering the reflective properties of light through molecular thin films. The purpose of this study was to develop a rapid assay for the determination of 3CP combining the Thermo Electron Bio Star OIA technology and the newly designed inhibitor compounds. The advantage of this assay was in its approach, in which therapeutic and diagnostic targets are the same thus allowing patients with detected rhinoviruses to receive optimal treatment. Three different biotinylated inhibitor compounds were synthesized. The length of the spacer between the inhibitor and biotin core was 5, 10, and 15 atoms. These compounds were incorporated into the OIA format for the HRV assay development. A rapid (20 min) OIA test was developed using a 15 atom spacer biotinylated inhibitor (4). Forty different HRV serotypes were studied and thirty three serotypes of these 40 were detected (80%).
Asunto(s)
Cisteína Endopeptidasas/análisis , Inmunoensayo , Inhibidores de Proteasas , Rhinovirus/aislamiento & purificación , Proteínas Virales/antagonistas & inhibidores , Proteínas Virales/análisis , Proteasas Virales 3C , Anticuerpos Antivirales , Proteínas Bacterianas/metabolismo , Biotinilación , Resfriado Común/diagnóstico , Resfriado Común/virología , Cisteína Endopeptidasas/inmunología , Células HeLa , Peroxidasa de Rábano Silvestre/metabolismo , Humanos , Estructura Molecular , Proteínas Virales/inmunologíaRESUMEN
The optimization of the pharmacokinetic performance of various 2-pyridone-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors following oral administration to either beagle dogs or CM-monkeys is described. The molecules described in this work are composed of a 2-pyridone-containing peptidomimetic binding determinant and an alpha,beta-unsaturated ester Michael acceptor moiety which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme. Modification of the ester contained within these compounds is detailed along with alteration of the P(2) substituent present in the peptidomimetic portion of the inhibitors. The pharmacokinetics of several inhibitors in both dogs and monkeys are described (7 h plasma concentrations after oral administration) along with their human plasma stabilities, stabilities in incubations with human, dog, and monkey microsomes and hepatocytes, Caco-2 permeabilities, and aqueous solubilities. Compounds containing an alpha,beta-unsaturated ethyl ester fragment and either an ethyl or propargyl P(2) moiety displayed the most promising combination of 3C enzyme inhibition (k(obs)/[I] 170 000-223 000 M(-1) s(-1)), antiviral activity (EC(50) = 0.047-0.058 microM, mean vs seven HRV serotypes), and pharmacokinetics following oral administration (7 h dog plasma levels = 0.248-0.682 microM; 7 h CM-monkey plasma levels = 0.057-0.896 microM).
Asunto(s)
Antivirales/síntesis química , Antivirales/farmacología , Cisteína Endopeptidasas/metabolismo , Inhibidores de Proteasas/síntesis química , Inhibidores de Proteasas/farmacología , Piridonas/síntesis química , Piridonas/farmacología , Rhinovirus/enzimología , Proteínas Virales/metabolismo , Proteasas Virales 3C , Animales , Antivirales/farmacocinética , Disponibilidad Biológica , Proteínas Sanguíneas/metabolismo , Células CACO-2 , Perros , Diseño de Fármacos , Semivida , Hepatocitos/metabolismo , Humanos , Técnicas In Vitro , Indicadores y Reactivos , Macaca fascicularis , Espectroscopía de Resonancia Magnética , Masculino , Microsomas Hepáticos/metabolismo , Inhibidores de Proteasas/farmacocinética , Unión Proteica , Rhinovirus/efectos de los fármacos , Solubilidad , Relación Estructura-ActividadRESUMEN
Utilizing the tools of parallel synthesis and structure-based design, a new class of Michael acceptor-containing, irreversible inhibitors of human rhinovirus 3C protease (HRV 3CP) was discovered. These inhibitors are shown to inhibit HRV-14 3CP with rates of inactivation ranging from 886 to 31 400 M(-1) sec(-1). These inhibitors exhibit antiviral activity when tested against HRV-14 infected H1-HeLa cells, with EC(50) values ranging from 1.94 to 0.15 microM. No cytotoxicity was observed at the limits of the assay concentration. A crystal structure of one of the more potent inhibitors covalently bound to HRV-2 3CP is detailed. These compounds were also tested against HRV serotypes other than type 14 and were found to have highly variable activities.
Asunto(s)
Antivirales/síntesis química , Inhibidores Enzimáticos/síntesis química , Rhinovirus/efectos de los fármacos , Proteínas Virales/antagonistas & inhibidores , Proteasas Virales 3C , Antivirales/química , Antivirales/farmacología , Técnicas Químicas Combinatorias , Cristalografía por Rayos X , Cisteína Endopeptidasas , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Células HeLa , Humanos , Unión Proteica , Rhinovirus/química , Relación Estructura-ActividadRESUMEN
The structure-based design, chemical synthesis, and biological evaluation of various 2-pyridone-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of a peptidomimetic binding determinant and a Michael acceptor moiety, which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme. The 2-pyridone-containing inhibitors typically display improved 3CP inhibition properties relative to related peptide-derived molecules along with more favorable antiviral properties. The cocrystal structure of one pyridone-derived 3CP inhibitor complexed with HRV-2 3CP is also described along with certain ab initio conformation analyses. Optimization of the 2-pyridone-containing compounds is shown to provide several highly active 3CP inhibitors (k(obs)/[I] > 500,00 M(-1) s(-1)) that function as potent antirhinoviral agents (EC(50) = <0.05 microM) against multiple virus serotypes in cell culture. One 2-pyridone-containing 3CP inhibitor is shown to be bioavailable in the dog after oral dosing (F = 48%).
Asunto(s)
Antivirales/síntesis química , Péptidos/química , Inhibidores de Proteasas/síntesis química , Piridonas/síntesis química , Rhinovirus/enzimología , Proteínas Virales/antagonistas & inhibidores , Proteasas Virales 3C , Administración Oral , Animales , Antivirales/química , Antivirales/farmacología , Disponibilidad Biológica , Cristalografía por Rayos X , Cisteína Endopeptidasas , Perros , Estabilidad de Medicamentos , Humanos , Técnicas In Vitro , Ligandos , Microsomas Hepáticos/metabolismo , Modelos Moleculares , Imitación Molecular , Inhibidores de Proteasas/química , Inhibidores de Proteasas/farmacología , Unión Proteica , Piridonas/química , Piridonas/farmacología , Relación Estructura-ActividadRESUMEN
The structure-based design, chemical synthesis, and biological evaluation of bicyclic 2-pyridone-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. An optimized compound is shown to exhibit antiviral activity when tested against a variety of HRV serotypes (EC(50)'s ranging from 0.037 to 0.162 microM).